Sequoia Financial Advisors LLC Purchases 25,504 Shares of The Cooper Companies, Inc. $COO

Key Points

• Sequoia Financial Advisors increased its Cooper Companies stake by 290.4% in the second quarter, acquiring 25,504 additional shares for a total holding valued at approximately $2.46 million.
• Cooper Companies reported quarterly EPS of $1.15, beating the $1.12 consensus, but revenue of about $1.07 billion fell short of expectations amid CooperVision destocking and weaker near-term demand.
• The company authorized a $3 billion share-repurchase program, while lowering fiscal 2026 EPS guidance to $4.51–$4.55. Analysts maintain a consensus “Hold” rating with an average target price of $71.47.

Sequoia Financial Advisors LLC lifted its position in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 290.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 34,286 shares of the medical device company's stock after acquiring an additional 25,504 shares during the period. Sequoia Financial Advisors LLC's holdings in Cooper Companies were worth $2,459,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. Root Financial Partners LLC boosted its stake in shares of Cooper Companies by 104.5% in the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company's stock valued at $26,000 after purchasing an additional 162 shares in the last quarter. Avalon Trust Co bought a new stake in Cooper Companies in the second quarter worth approximately $25,000. SJS Investment Consulting Inc. raised its holdings in shares of Cooper Companies by 107.5% during the first quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company's stock valued at $26,000 after purchasing an additional 187 shares during the period. Elevation Wealth Partners LLC raised its position in shares of Cooper Companies by 1,136.4% during the second quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company's stock worth $29,000 after purchasing an additional 375 shares during the period. Finally, Continuum Advisory LLC bought a new position in shares of Cooper Companies in the second quarter valued at $30,000. 24.39% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on COO. The Goldman Sachs Group set a $61.00 target price on Cooper Companies in a research report on Wednesday, May 27th. Stifel Nicolaus set a $70.00 price objective on shares of Cooper Companies and gave the company a "buy" rating in a report on Thursday. Citigroup reaffirmed a "neutral" rating and issued a $60.00 price target (down from $80.00) on shares of Cooper Companies in a report on Thursday. KeyCorp reaffirmed a "sector weight" rating on shares of Cooper Companies in a research note on Friday, June 5th. Finally, BNP Paribas Exane decreased their target price on Cooper Companies from $95.00 to $92.00 and set an "outperform" rating on the stock in a research note on Monday, June 8th. Five analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $71.47.

Key Headlines Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper reported adjusted fiscal Q3 earnings of $1.15 per share, ahead of the approximately $1.11–$1.12 consensus, with earnings up from $0.49 a year earlier. Cost controls and continued fertility-related growth helped offset weakness elsewhere. Cooper Companies Bets on Fertility Growth Despite Weakness in CooperVision
• Positive Sentiment: The board authorized an additional $1 billion of repurchases, bringing the total buyback authorization to $3 billion. The program could support per-share earnings and signal management believes COO shares are undervalued. Cooper Outlines Q4 EPS and Adds to Buyback Authorization
• Neutral Sentiment: Cooper completed a strategic review but chose not to pursue a sale or separate transaction for CooperSurgical. Keeping the business preserves its fertility-growth opportunity, but investors had apparently anticipated a potential deal or value-unlocking action. Cooper Cos. Stock Drops After Soft Outlook and No Deal
• Negative Sentiment: Revenue rose only about 1% to $1.066 billion, missing the roughly $1.10 billion consensus. U.S. channel destocking and inventory reductions pressured CooperVision, raising concerns about near-term demand and sales momentum. COO Q3 Earnings Top Estimates, Revenues Miss on Destocking
• Negative Sentiment: Management reduced fiscal 2026 earnings guidance to $4.51–$4.55 per share and issued fourth-quarter guidance of $1.05–$1.09, below prior expectations. The weaker outlook triggered multiple analyst downgrades and price-target cuts, including from Baird, UBS, JPMorgan and William Blair.
• Negative Sentiment: Law firms have announced securities-fraud investigations connected with the post-earnings decline. These notices are often promotional, but they add to negative investor sentiment and potential legal uncertainty. Securities Fraud Investigation Into Cooper Companies Announced

Cooper Companies Stock Performance

NASDAQ COO opened at $53.91 on Monday. The company has a current ratio of 1.22, a quick ratio of 0.73 and a debt-to-equity ratio of 0.23. The Cooper Companies, Inc. has a 1-year low of $51.01 and a 1-year high of $89.83. The stock has a 50-day moving average of $71.62 and a 200-day moving average of $69.61. The firm has a market cap of $10.25 billion, a PE ratio of 18.40, a price-to-earnings-growth ratio of 2.19 and a beta of 0.82.

Cooper Companies (NASDAQ:COO - Get Free Report) last issued its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.03. The firm had revenue of $1.07 billion for the quarter, compared to analysts' expectations of $1.10 billion. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. The business's revenue was up .5% on a year-over-year basis. During the same quarter last year, the business earned $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, sell-side analysts forecast that The Cooper Companies, Inc. will post 4.53 EPS for the current year.

Cooper Companies declared that its Board of Directors has initiated a stock repurchase plan on Wednesday, September 9th that authorizes the company to buyback $3.00 billion in outstanding shares. This buyback authorization authorizes the medical device company to reacquire up to 22.7% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's board of directors believes its shares are undervalued.

About Cooper Companies

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.